INTRODUCTION {#s1}
============

Breast cancer (BC), one of the most common malignant tumors among women worldwide, has the highest mortality rate in female cancer. Its incidence rate is increasing year by year and the patients are becoming younger and younger in the world \[[@R1], [@R2]\]. BC is the result of the interaction of environmental and genetic factors. Under the same carcinogenic factors, only a small fraction of people develop BC, which suggests that the genetic background differences lead to individual differences in BC susceptibility \[[@R3]\].

In recent years, genome-wide association study (GWAS) provides a good technical support for the study on the susceptibility loci with high variation frequency and low penetrance \[[@R4]\]. Large numbers of BC related susceptibility genes and single nucleotide polymorphism sites have been found through GWAS, such as LSP1, MAP3K1, FGFR2, TGFB1, TOX3, etc \[[@R5]\]. The discovery of these genes will have an important impact on the prevention and treatment of BC, especially FGFR2 (rs2981582, rs2420946 and rs2981578). FGFR2 gene is located in 10q26, and contains at least 22 exons \[[@R6]\]. FGFR2 is a member of the tyrosine kinase receptor family. It is a transmembrane protein, and is mainly composed of three parts: extracellular region, transmembrane region and intracellular region. The extracellular segment has three immunoglobulin like protein functional areas. Through the combination with FGFs, the functional areas could activate the tyrosine kinase activity and induce receptor tyrosine phosphorylation. It also starts series of cascade reaction through the RAS-MAPK, JAK-STATs and PLC-Y signal system, and then regulate the transcription of downstream genes involve in the body\'s physiological and pathological activities, such as cell proliferation, differentiation, migration and apoptosis, angiogenesis, skeletal development. So FGFR2 plays an important role in the processes of human growth and development \[[@R7]\].

Lots of researches have reported the association between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk. However, due to differences in ethnic and regional and other factors, the conclusions of related reports are still inconclusive. Raskin et al \[[@R8]\] found FGFR2 rs2420946 was significantly associated with BC risk in Ashkenazi and Sephardi Jews, with a similar but not significant trend in Arabs. Liang et al\'s \[[@R9]\] study indicated that each of thesingle nucleotide polymorphisms (SNPs) (rs2981582and rs2420946) was significantly associated with increased BC risk, and the risk was the highest for those carrying the 2 mutation sites at the same time. While, there are also some different reports. Liu et al \[[@R10]\] found that FGFR2 rs2420946was not significantly correlated with the occurrence of BC in Chinese population. These different conclusions may result from the diversity of genetic background and carcinogenic factors, therefore, further studies in different populations should be implemented to assess the correlation between SNPs and BC risk. Although five meta-analysis \[[@R11]--[@R15]\] on the associations between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk had been implemented, yet the results remained inconclusive and some just no subgroup. Therefore, we carried out this meta-analysis on all the included case-control researches to make a more accurate assessment of the relationship.

RESULTS {#s2}
=======

Characteristics of included papers {#s2_1}
----------------------------------

The specific search process is shown in Figure [1](#F1){ref-type="fig"}. A total of 563 references were preliminarily identified at first based on our selection strategy. We also identified 2 papers through other sources. 454 records left after removing repeated studies. We refer to titles or abstracts of all the included literatures, and then removed obviously irrelevant papers. In the end, the whole of the rest of the papers were checked based on the inclusion and exclusion criteria. Finally, 35 studies on FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and the occurrence of BC were eventually included in our study. Characteristics of eligible analysis are shown in Table [1](#T1){ref-type="table"}. The 35 case-control papers were published between 2007 and 2015, among them, 1 study was performed in African, 17 in Asian, 14 in Caucasians and 3 in both Asian and Caucasians. All studies were case-controlled.

![Flow chart of studies selection in this meta-analysis](oncotarget-08-3454-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  First author                Year   Country    Ethnicity   Source of controls   Genotyping medthod       Number(case/control)   HWE
  --------------------------- ------ ---------- ----------- -------------------- ------------------------ ---------------------- ----------
  rs2981582 (C\>T)                                                                                                               
  Kawase \[[@R20]\]           2009   Japan      Asian       HB                   TaqMan                   455/912                0.773315
  Hu \[[@R25]\]               2011   China      Asian       PB                   PCR-RFLP                 203/200                0.758366
  Li \[[@R26]\]               2011   China      Asian       HB                   MassArray                401/441                0.219207
  Chen \[[@R27]\]             2012   China      Asian       PB                   PCR-SSCP                 388/424                0.048991
  Butt \[[@R28]\]             2012   Swedish    Caucasian   PB                   MassArray                713/1399               0.816442
  Shan \[[@R29]\]             2012   Tunisian   African     PB                   TaqMan                   600/358                0.060883
  Fu \[[@R30]\]               2012   China      Asian       HB                   iPLEX                    118/104                0.474243
  Campa \[[@R31]\]            2011   Mixed      Mixed       PB                   Taqman                   8313/11594             0.607558
  Slattery \[[@R32]\]         2011   American   Caucasian   PB                   Taqman                   1734/2040              0.822253
  Han \[[@R33]\]              2011   Korean     Asian       PB                   Taqman                   3232/3489              0.361342
  Tamimi \[[@R34]\]           2010   Swedish    Caucasian   PB                   Taqman                   680/734                0.535243
  Gorodnova \[[@R35]\]        2010   Russian    Caucasian   NA                   Taqman                   140/174                0.000621
  Ren \[[@R36]\]              2010   China      Asian       HB                   Taqman                   956/471                0.024883
  McInerney \[[@R37]\]        2009   British    Caucasian   PB                   KASPar                   941/997                0.83057
  Boyarskikh \[[@R38]\]       2009   Russia     Caucasian   PB                   Taqman                   744/628                0.659988
  Garcia-Closas \[[@R39]\]    2008   Mixed      Mixed       PB, HB               Taqman                   16882/26058            0.892667
  Liang \[[@R9]\]             2008   China      Asian       HB                   Taqman                   1026/1062              0.97418
  Antoniou \[[@R40]\]         2008   European   Mixed       NA                   Taqman, MALDI-TOF        4990/4301              0.596563
  Zhao \[[@R41]\]             2010   China      Asian       HB                   PCR-RFLP                 956/471                0.024883
  Xi \[[@R42]\]               2014   China      Asian       HB                   MALDI-TOF                815/849                0.959015
  Campa \[[@R19]\]            2015   Mixed      Caucasian   PB                   TaqMan                   1234/12231             0.779613
  Slattery \[[@R43]\]         2013   American   Caucasian   PB                   multiplexed bead array   3560/4138              0.364662
  Chan \[[@R44]\]             2012   China      Asian       HB                   Taqman                   1168/1475              0.164674
  Dai \[[@R45]\]              2012   China      Asian       HB                   TaqMan                   1768/1844              0.423521
  Jara \[[@R46]\]             2013   Chile      Caucasian   PB                   TaqMan                   351/802                0.138274
  Liang \[[@R18]\]            2015   China      Asian       HB                   MassARRAY                607/856                0.298476
  Liu \[[@R47]\]              2013   China      Asian       HB                   PCR-RFLP                 203/200                0.758366
  Murillo-Zamora \[[@R48]\]   2013   Mexico     Caucasian   PB                   Multiplexed assays       687/907                0.351295
  Ottini \[[@R49]\]           2013   Italy      Caucasian   PB                   TaqMan                   413/745                0.76716
  Ozgoz \[[@R50]\]            2013   Turkey     Caucasian   PB                   PCR-RFLP                 31/30                  0.281979
  Siddiqui \[[@R51]\]         2014   India      Asian       HB                   PCR-RFLP                 368/484                0.526174
  rs2420946 (C\>T)                                                                                                               
  Raskin \[[@R8]\]            2008   USA        Caucasian   PB                   TaqMan                   1480/1474              0.224235
  Kawase \[[@R20]\]           2009   Japan      Asian       HB                   TaqMan                   453/912                0.519554
  Liu \[[@R10]\]              2009   China      Asian       PB                   PCR-RFLP                 106/116                0.361602
  Hu \[[@R25]\]               2011   China      Asian       PB                   PCR-RFLP                 203/200                0.325727
  Li \[[@R26]\]               2011   China      Asian       HB                   MassArray                391/432                0.703117
  Fu \[[@R30]\]               2012   China      Asian       HB                   iPLEX                    118/104                0.505449
  Liang \[[@R9]\]             2008   China      Asian       HB                   Taqman                   1020/1050              0.413194
  Hunter \[[@R52]\]           2007   USA        Caucasian   PB                   Taqman                   2912/3212              0.293864
  Jara \[[@R46]\]             2013   Chile      Caucasian   PB                   TaqMan                   351/802                0.292806
  Liang \[[@R18]\]            2015   China      Asian       HB                   MassARRAY                603/847                0.063645
  Liu \[[@R47]\]              2013   China      Asian       HB                   PCR-RFLP                 203/200                0.325727
  rs2981578 (A\>G)                                                                                                               
  Chen \[[@R27]\]             2012   China      Asian       PB                   PCR-SSCP                 378/458                0.290218
  Lin \[[@R53]\]              2012   Taiwan     Asian       PB                   PCR-RFLP                 87/70                  0.724138
  Siddiqui \[[@R51]\]         2014   India      Asian       HB                   PCR-RFLP                 368/484                0.278456

HWE: hardy-weinberg equilibrium; PB: population based; HB: hospital-based.

Meta-analysis results {#s2_2}
---------------------

The FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms genotype distribution and allele frequencies incase groups and control groups were shown in Table [2](#T2){ref-type="table"}. Main results of our study were shown in Table [3](#T3){ref-type="table"}. There were 31 studies with 54,677 cases and 80,418 controls for FGFR2 rs2981582 variants. As shown in Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"} and Figure [3](#F3){ref-type="fig"}, the pooled results indicated that the correlation between FGFR2 rs2981582 polymorphism and the occurrence of BC was significant in any genetic model: Allele model (OR: 1.23; 95% CI: 1.19- 1.26; P\< 0.00001), Dominant model (OR: 1.29; 95% CI: 1.24-1.34; P\< 0.00001), Recessive model (OR: 1.35; 95% CI: 1.31-1.40; P\<0.00001), Homozygous genetic model (OR: 1.50; 95% CI: 1.42-1.58; P\< 0.00001), Heterozygote comparison (OR: 1.22; 95% CI: 1.17-1.27; P\< 0.00001). In ethnicity specific analysis, FGFR2 rs2981582 were significantly associated with BC risk both in Asians (Allele model: OR=1.19, 95% CI=1.15- 1.24, P\< 0.00001; Dominant model: OR=1.23, 95% CI=1.17-1.29, P\< 0.00001; Recessive model: OR=1.31, 95% CI=1.21-1.42, P\< 0.00001; Homozygous genetic model: OR=1.42, 95% CI=1.31-1.54, P\< 0.00001; Heterozygote comparison: OR=1.18, 95% CI=1.12-1.25, P\< 0.00001) and Caucasians (Allele model: OR=1.25, 95% CI=1.21-1.30, P\< 0.00001; Dominant model: OR=1.33, 95% CI=1.26-1.40, P\< 0.00001; Recessive model: OR=1.37, 95% CI=1.28-1.46, P\< 0.00001; Homozygous genetic model: OR=1.56, 95% CI=1.45-1.68, P\< 0.00001; Heterozygote comparison: OR=1.26, 95% CI=1.19-1.33, P\< 0.00001). We didn\'t discuss the African subgroup for just one study from African. The analysis in different source of controls showed the same association between FGFR2 rs2981582 polymorphism and BC susceptibility both in HB(Allele model: OR=1.22, 95% CI=1.16-1.27, P\< 0.00001; Dominant model: OR=1.27, 95% CI=1.20-1.35, P\< 0.00001; Recessive model: OR=1.31, 95% CI=1.20-1.44, P\< 0.00001; Homozygous genetic model: OR=1.45, 95% CI=1.31-1.60, P\< 0.00001; Heterozygote comparison: OR=1.23, 95% CI=1.15-1.31, P\< 0.00001) and PB(Allele model: OR=1.24, 95% CI=1.19-1.29, P\< 0.00001; Dominant model: OR=1.31, 95% CI=1.23-1.40, P\< 0.00001; Recessive model: OR=1.35, 95% CI=1.29-1.42, P\< 0.00001; Homozygous genetic model: OR=1.50, 95% CI=1.43-1.58, P\< 0.00001; Heterozygote comparison: OR=1.23, 95% CI=1.15-1.31, P\< 0.00001).

###### Polymorphisms genotype distribution and allele frequency in cases and controls

  First author                Genotype (N)   Allele frequency (N)                                                                        
  --------------------------- -------------- ---------------------- ------ ------ ------- ------ ------- ------- ------- ------- ------- -------
  rs2981582 (C\>T)            Total          TT                     TC     CC     Total   TT     TC      CC      T       C       T       C
  Kawase \[[@R20]\]           455            42                     192    221    912     63     347     502     276     634     473     1351
  Hu \[[@R25]\]               203            47                     78     78     200     26     95      79      172     234     147     253
  Li \[[@R26]\]               401            54                     180    167    441     60     189     192     288     514     309     573
  Chen \[[@R27]\]             388            48                     208    132    424     60     224     140     304     472     344     504
  Butt \[[@R28]\]             713            124                    356    233    1399    185    653     561     604     822     1023    1775
  Shan \[[@R29]\]             600            147                    315    138    358     64     154     140     609     591     282     434
  Fu \[[@R30]\]               118            21                     55     42     104     8      47      49      97      139     63      145
  Campa \[[@R31]\]            8313           1568                   3951   2794   11594   1718   5456    4420    7087    9539    8892    14296
  Slattery \[[@R32]\]         1734           315                    884    535    2040    318    981     741     1514    1954    1617    2463
  Han \[[@R33]\]              3232           342                    1393   1497   3489    281    1457    1751    2077    4387    2019    4959
  Tamimi \[[@R34]\]           680            136                    304    240    734     91     324     319     576     784     506     962
  Gorodnova \[[@R35]\]        140            23                     67     50     174     25     54      95      113     167     104     244
  Ren \[[@R36]\]              956            130                    400    426    471     56     181     234     660     1252    293     649
  McInerney \[[@R37]\]        941            214                    458    269    997     179    483     335     886     996     841     1153
  Boyarskikh \[[@R38]\]       744            126                    371    247    628     71     273     284     623     865     415     841
  Garcia-Closas \[[@R39]\]    16882          3243                   8218   5421   26058   3747   12255   10056   14704   19060   19749   32367
  Liang \[[@R9]\]             1026           119                    460    447    1062    91     439     532     698     1354    621     1503
  Antoniou \[[@R40]\]         4990           936                    2407   1647   4301    703    2051    1547    4279    5701    3457    5145
  Zhao \[[@R41]\]             956            130                    400    426    471     56     181     234     660     1252    293     649
  Xi \[[@R42]\]               815            100                    423    292    849     94     376     379     623     1007    564     1134
  Campa \[[@R19]\]            1234           241                    608    385    12231   1847   5793    4591    1090    1378    9487    14975
  Slattery \[[@R43]\]         3560           708                    1749   1103   4138    638    2009    1491    3165    3955    3285    4991
  Chan \[[@R44]\]             1168           155                    527    486    1475    162    618     695     837     1499    942     2008
  Dai \[[@R45]\]              1768           216                    820    732    1844    164    796     884     1252    2284    1124    2564
  Jara \[[@R46]\]             351            80                     178    93     802     141    366     295     338     364     648     956
  Liang \[[@R18]\]            607            103                    266    238    856     111    375     370     472     742     597     1115
  Liu \[[@R47]\]              203            47                     78     78     200     26     95      79      172     234     147     253
  Murillo-Zamora \[[@R48]\]   687            145                    309    233    907     139    415     353     599     775     693     1121
  Ottini \[[@R49]\]           413            98                     205    110    745     139    361     245     401     425     639     851
  Ozgoz \[[@R50]\]            31             9                      16     6      30      10     12      8       34      28      32      28
  Siddiqui \[[@R51]\]         368            56                     168    144    484     53     205     226     280     456     311     657
  rs2420946 (C\>T)            Total          TT                     TC     CC     Total   TT     TC      CC      T       C       T       C
  Raskin \[[@R8]\]            1480           356                    715    409    1474    285    700     489     1427    1533    1270    1678
  Kawase \[[@R20]\]           453            60                     226    167    912     99     416     397     346     560     614     1210
  Liu \[[@R10]\]              106            16                     51     39     116     21     51      44      83      129     93      139
  Hu \[[@R25]\]               203            50                     92     61     200     34     105     61      192     214     173     227
  Li \[[@R26]\]               391            74                     186    131    432     68     202     162     334     448     338     526
  Fu \[[@R30]\]               118            25                     55     38     104     9      48      47      105     131     66      142
  Liang \[[@R9]\]             1020           163                    519    338    1050    142    505     403     845     1195    789     1311
  Hunter \[[@R52]\]           2912           603                    1409   900    3212    484    1562    1166    2615    3209    2530    3894
  Jara \[[@R46]\]             351            85                     175    91     802     143    374     285     345     357     660     944
  Liang \[[@R18]\]            603            116                    297    190    847     145    379     323     529     677     669     1025
  Liu \[[@R47]\]              203            50                     92     61     200     34     105     61      192     214     173     227
  rs2981578 (A\>G)            Total          GG                     GA     AA     Total   GG     GA      AA      G       A       G       A
  Chen \[[@R27]\]             378            150                    188    40     458     160    212     86      488     268     532     384
  Lin \[[@R53]\]              87             35                     39     13     70      21     36      13      109     65      78      62
  Siddiqui \[[@R51]\]         368            129                    185    54     484     151    228     105     443     293     530     438

###### Meta-analysis results

  Outcome or Subgroup          Studies   Participants   Statistical Method         Effect Estimate       P value      Heterogeneity   
  ---------------------------- --------- -------------- -------------------------- --------------------- ------------ --------------- -------
  Allele model                                                                                                                        
  rs2981582 (C\>T)             31        270190         OR (M-H, Random, 95% CI)   1.23 \[1.19, 1.26\]   \< 0.00001   41%             0.01
  Asian                        15        51892          OR (M-H, Fixed, 95% CI)    1.19 \[1.15, 1.24\]   \< 0.00001   0%              0.54
  Caucasian                    12        72106          OR (M-H, Fixed, 95% CI)    1.25 \[1.21, 1.30\]   \< 0.00001   4%              0.4
  HB                           12        36020          OR (M-H, Fixed, 95% CI)    1.22 \[1.16, 1.27\]   \< 0.00001   0%              0.87
  PB                           16        129080         OR (M-H, Random, 95% CI)   1.24 \[1.19, 1.29\]   \< 0.00001   46%             0.02
  rs2420946 (C\>T)             11        34378          OR (M-H, Fixed, 95% CI)    1.23 \[1.18, 1.29\]   \< 0.00001   0%              0.67
  Asian                        8         13916          OR (M-H, Fixed, 95% CI)    1.19 \[1.11, 1.28\]   \< 0.00001   0%              0.67
  Caucasian                    3         20462          OR (M-H, Fixed, 95% CI)    1.26 \[1.19, 1.33\]   \< 0.00001   0%              0.53
  HB                           6         12666          OR (M-H, Fixed, 95% CI)    1.20 \[1.12, 1.29\]   \< 0.00001   0%              0.61
  PB                           5         21712          OR (M-H, Fixed, 95% CI)    1.25 \[1.18, 1.32\]   \< 0.00001   0%              0.5
  rs2981578 (A\>G)             3         3690           OR (M-H, Fixed, 95% CI)    1.29 \[1.13, 1.47\]   0.0002       0%              0.93
  Dominant model                                                                                                                      
  rs2981582 (C\>T)             31        135095         OR (M-H, Random, 95% CI)   1.29 \[1.24, 1.34\]   \< 0.00001   46%             0.003
  Asian                        15        25946          OR (M-H, Fixed, 95% CI)    1.23 \[1.17, 1.29\]   \< 0.00001   0%              0.63
  Caucasian                    12        36053          OR (M-H, Fixed, 95% CI)    1.33 \[1.26, 1.40\]   \< 0.00001   16%             0.28
  HB                           12        18010          OR (M-H, Fixed, 95% CI)    1.27 \[1.20, 1.35\]   \< 0.00001   0%              0.89
  PB                           16        64540          OR (M-H, Random, 95% CI)   1.31 \[1.23, 1.40\]   \< 0.00001   55%             0.004
  rs2420946 (C\>T)             11        17189          OR (M-H, Fixed, 95% CI)    1.28 \[1.20, 1.37\]   \< 0.00001   0%              0.77
  Asian                        8         6958           OR (M-H, Fixed, 95% CI)    1.25 \[1.13, 1.39\]   \< 0.00001   0%              0.75
  Caucasian                    3         10231          OR (M-H, Fixed, 95% CI)    1.31 \[1.20, 1.42\]   \< 0.00001   0%              0.38
  HB                           6         6333           OR (M-H, Fixed, 95% CI)    1.28 \[1.15, 1.42\]   \< 0.00001   0%              0.73
  PB                           5         10856          OR (M-H, Fixed, 95% CI)    1.29 \[1.19, 1.40\]   \< 0.00001   0%              0.44
  rs2981578 (A\>G)             3         1845           OR (M-H, Fixed, 95% CI)    1.71 \[1.32, 2.21\]   \< 0.0001    0%              0.63
  Recessive model                                                                                                                     
  rs2981582 (C\>T)             31        135095         OR (M-H, Fixed, 95% CI)    1.35 \[1.31, 1.40\]   \< 0.00001   15%             0.24
  Asian                        15        25946          OR (M-H, Fixed, 95% CI)    1.31 \[1.21, 1.42\]   \< 0.00001   19%             0.24
  Caucasian                    12        36053          OR (M-H, Fixed, 95% CI)    1.37 \[1.28, 1.46\]   \< 0.00001   0%              0.74
  HB                           12        18010          OR (M-H, Fixed, 95% CI)    1.31 \[1.20, 1.44\]   \< 0.00001   0%              0.5
  PB                           16        64540          OR (M-H, Fixed, 95% CI)    1.35 \[1.29, 1.42\]   \< 0.00001   0%              0.45
  rs2420946 (C\>T)             11        17189          OR (M-H, Fixed, 95% CI)    1.36 \[1.26, 1.48\]   \< 0.00001   4%              0.4
  Asian                        8         6958           OR (M-H, Fixed, 95% CI)    1.27 \[1.12, 1.45\]   0.0003       8%              0.37
  Caucasian                    3         10231          OR (M-H, Fixed, 95% CI)    1.42 \[1.29, 1.57\]   \< 0.00001   0%              0.61
  HB                           6         6333           OR (M-H, Fixed, 95% CI)    1.27 \[1.11, 1.46\]   0.0006       4%              0.39
  PB                           5         10856          OR (M-H, Fixed, 95% CI)    1.41 \[1.28, 1.56\]   \< 0.00001   0%              0.46
  rs2981578 (A\>G)             3         1845           OR (M-H, Fixed, 95% CI)    1.24 \[1.02, 1.50\]   0.03         0%              0.75
  Homozygous genetic model                                                                                                            
  rs2981582 (C\>T)             31        71786          OR (M-H, Random, 95% CI)   1.50 \[1.42, 1.58\]   \< 0.00001   33%             0.04
  Asian                        15        14673          OR (M-H, Fixed, 95% CI)    1.42 \[1.31, 1.54\]   \< 0.00001   2%              0.43
  Caucasian                    12        18824          OR (M-H, Fixed, 95% CI)    1.56 \[1.45, 1.68\]   \< 0.00001   0%              0.73
  HB                           12        10192          OR (M-H, Fixed, 95% CI)    1.45 \[1.31, 1.60\]   \< 0.00001   0%              0.69
  PB                           16        34101          OR (M-H, Fixed, 95% CI)    1.50 \[1.43, 1.58\]   \< 0.00001   32%             0.11
  rs2420946 (C\>T)             11        8925           OR (M-H, Fixed, 95% CI)    1.52 \[1.39, 1.66\]   \< 0.00001   0%              0.54
  Asian                        8         3629           OR (M-H, Fixed, 95% CI)    1.40 \[1.21, 1.62\]   \< 0.00001   0%              0.57
  Caucasian                    3         5296           OR (M-H, Fixed, 95% CI)    1.60 \[1.43, 1.79\]   \< 0.00001   0%              0.56
  HB                           6         3303           OR (M-H, Fixed, 95% CI)    1.43 \[1.22, 1.66\]   \< 0.00001   0%              0.53
  PB                           5         5622           OR (M-H, Fixed, 95% CI)    1.57 \[1.41, 1.76\]   \< 0.00001   0%              0.47
  rs2981578 (A\>G)             3         957            OR (M-H, Fixed, 95% CI)    1.80 \[1.36, 2.39\]   \< 0.0001    0%              0.8
  Heterozygote genetic model                                                                                                          
  rs2981582 (C\>T)             31        114046         OR (M-H, Random, 95% CI)   1.22 \[1.17, 1.27\]   \< 0.00001   42%             0.007
  Asian                        15        23025          OR (M-H, Fixed, 95% CI)    1.18 \[1.12, 1.25\]   \< 0.00001   1%              0.44
  Caucasian                    12        30051          OR (M-H, Fixed, 95% CI)    1.26 \[1.19, 1.33\]   \< 0.00001   26%             0.19
  HB                           12        15893          OR (M-H, Fixed, 95% CI)    1.23 \[1.15, 1.31\]   \< 0.00001   0%              0.75
  PB                           16        54285          OR (M-H, Random, 95% CI)   1.23 \[1.15, 1.31\]   \< 0.00001   52%             0.009
  rs2420946 (C\>T)             11        14127          OR (M-H, Fixed, 95% CI)    1.21 \[1.13, 1.29\]   \< 0.00001   0%              0.69
  Asian                        8         5852           OR (M-H, Fixed, 95% CI)    1.21 \[1.08, 1.34\]   0.0005       0%              0.62
  Caucasian                    3         8275           OR (M-H, Fixed, 95% CI)    1.21 \[1.11, 1.32\]   \< 0.0001    0%              0.37
  HB                           6         5348           OR (M-H, Fixed, 95% CI)    1.23 \[1.10, 1.38\]   0.0002       0%              0.66
  PB                           5         8779           OR (M-H, Fixed, 95% CI)    1.19 \[1.09, 1.30\]   \< 0.0001    0%              0.42
  rs2981578 (A\>G)             3         1199           OR (M-H, Fixed, 95% CI)    1.65 \[1.26, 2.16\]   0.0003       0%              0.51

CI: Confidence interval.
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![Forest plots of rs2981582 (C\>T) polymorphism and breast cancer risk stratified by Source of controls (Recessive model TT vs. CC + TC)](oncotarget-08-3454-g003){#F3}

For rs2420946, 11 studies with 7,840 cases and 9,349 controls were included to assess the association. As shown in Table [3](#T3){ref-type="table"}, Figure [4](#F4){ref-type="fig"} and Figure [5](#F5){ref-type="fig"}, the pooled ORs suggested that rs2420946 was significantly associated with BC susceptibility in all the five genetic models: Allele model 1.23 (95% CI: 1.18-1.29; P\< 0.00001), Dominant model 1.28 (95% CI: 1.20-1.37; P\< 0.00001), Recessive model 1.36 (95% CI: 1.26-1.48; P\< 0.00001), Homozygous genetic model 1.52 (95% CI: 1.39-1.66; P\< 0.00001), Heterozygote comparison 1.21 (95% CI: 1.13-1.29; P\< 0.00001). When stratified by Ethnicity and Source of controls, the results showed that FGFR2 rs2420946 was significantly associated with BC risk in Asians, Caucasians, HB and PB.
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3 papers with 833 cases and 1012 controls were adopted to evaluate the association between the rs2981578 polymorphism and the BC risk. As shown in Table [3](#T3){ref-type="table"}, Figure [6](#F6){ref-type="fig"}, the association between rs2981578 variant and BC susceptibility was also significant in any genetic model (Allele model: OR= 1.29, 95% CI= 1.13-1.47, P= 0.0002; Dominant model: OR= 1.71, 95% CI= 1.32-2.21, P\< 0.0001; Recessive model: OR= 1.24, 95% CI= 1.02-1.50, P= 0.03; Homozygous genetic model: OR= 1.80, 95% CI= 1.36-2.39, P\< 0.0001; Heterozygote comparison: OR= 1.65, 95% CI= 1.26-2.16, P= 0.0003).
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Sensitivity analyses {#s2_3}
--------------------

As shown in Table [1](#T1){ref-type="table"}, all the studies conformed to the balance of HWE in controls except Chen's(2012), Gorodnova's(2012), Ren's(2012), Zhao's(2012) studies(P\<0.05) in rs2981582 group, however, after performing the sensitivity analyses, the overall outcomes were no statistically significant change when removing any of the articles, indicating that our study has good stability and reliability.

Detection for heterogeneity {#s2_4}
---------------------------

Heterogeneity among studies was obtained by *Q* statistic. Random-effect models were applied if *p*-value of heterogeneity tests were less than 0.1 (*p* ≤ 0.1), otherwise, fixed-effect models were selected (Table [3](#T3){ref-type="table"}).

Publication bias {#s2_5}
----------------

As Figure [7](#F7){ref-type="fig"} indicated, the symmetrical funnel plot indicated that there is no significant publication bias in the total population. We use Begg\'s funnel plot and Egger test to evaluate the published bias, no significant publication bias was found in the Begg\'s test and Egger\'s test (P\>0.05).

![Funnel plot assessing evidence of publication bias\
**A**. rs2981582 (C\>T) (Recessive model TT vs. CC + TC). **B**. rs2420946 (C\>T) (Dominant model TC + TT vs. CC). **C**. rs2981578 (A\>G) (Allele model G vs. A). SE: standard error; OR: odds ratio.](oncotarget-08-3454-g007){#F7}

DISCUSSION {#s3}
==========

FGFR2 has been proved to be associated with many diseases, especially the relationship between FGFR2 and cancer, which has become a hot research topic in recent years \[[@R16]\]. GWAS analysis revealed that FGFR2 gene was one of the BC susceptibility genes. There are 8 SNPs(rs35054928, rs2981578, rs2912778, rs2912781, rs35393331, rsl0736303, rs7895676, rs33971856) in its second intron and the SNPs of FGFR2 have become the hotspot in BC susceptibility gene study \[[@R17]--[@R19]\]. But the difference of SNPs allele frequency and LD structure reflects the difference of the genetic variation in the race, so the occurrence and characteristics of BC were different. Therefore, a variation in one study does not have the same risk impact on other crowds. This requires repeated studies on previously related locis in multiple populations worldwide.

Lots of researches have reported the association between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk. However, due to differences in ethnic and regional and other factors, the conclusions of related reports are still inconclusive. Thus, we conducted the meta-analysis to evaluate the relationship between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk.

In our study, there were 31 studies with 54,677 cases and 80,418 controls for FGFR2 rs2981582 variants. In the total population, the pooled results indicated that the correlation between FGFR2 rs2981582 polymorphism and the occurrence of BC was significant in any genetic model. Furthermore, in ethnicity-specific analysis, FGFR2 rs2981582 were also significantly associated with BC risk both in Asians and Caucasians. We didn\'t discuss the African subgroup for just one study was from African. The analysis in different source of controls showed the same association between FGFR2 rs2981582 polymorphism and BC susceptibility both in HB and PB, indicating that both hospital populations and general populations followed the same relationship. For rs2420946, 11 studies with 7,840 cases and 9,349 controls were included to assess the association. In the total population, the pooled ORs suggested that rs2420946 was significantly associated with BC susceptibility in all the five genetic models. When stratified by ethnicity and source of controls, the results showed the same association in Asians, Caucasians, hospital populations and general populations, indicating that different genetic backgrounds and living environment were not strong enough to change these associations. All the results for the two variants (rs2981582, rs2420946) were partially consistent with the consequences of Wang\'s \[[@R13]\], Peng\'s \[[@R14]\], Zhang\'s \[[@R12]\] and Jia\'s \[[@R15]\] meta-analysis, while they didn\'t conduct analysis in different source of controls, making our results more valuable. Furthermore, they didn\'t use all the five genetic models(allele model, dominant model, recessive model, homozygous model and heterozygous model) to assess the strength of association. Wang\'s \[[@R13]\] study also reported that the association appeared to be much stronger for estrogen receptor-positive and progesterone receptor-positive BC, which was not analyzed in our study. Peng\'s \[[@R14]\] study was conducted on the base of present mata-ananlyses, which may missed some individual studies with larger sample sizes, and this type meta-analysis may not appropriate. In Zhang\'s \[[@R12]\] study, the increased risk was found in the subgroup of postmenopausal women for rs2420946. However, only one study \[[@R20]\] reported that risk in premenopausal women. For Jia\'s \[[@R15]\] study, in the ethnicity subgroup, using Non-Caucasians represent different ethnicities may cause some heterogeneity.

Three articles with 833 cases and 1012 controls were adopted to evaluate the association between the rs2981578 polymorphism and the BC risk. As the preceding two variants, the association between rs2981578 variant and BC susceptibility was also significant in any genetic model. For just only 3 studies, no stratified study was conducted for rs2981578 polymorphism. However, in Zhou\'s \[[@R11]\] meta-analysis, they found that rs2981578 polymorphism might decrease BC risk. This may result from the literature selection bias. While the sample size of our study for rs2981578 was so small, data from a large sample of multiple centers is still needed to assess the association.

Our meta-analysis has several limitations. First, our study is a summary of the data. For lack of all individual raw data, we could not assess the cancer risk stratified by other covariates including age, sex, environment, hormone level, menopause age and other risk factors. We also cannot analyze the potential interaction of gene-environment and gene-gene. Second, only published papers were included in our meta-analysis, there still may be some unpublished studies which are in line with the conditions. Therefore, publication bias may exist even no statistical evidence was found in the meta-analysis. Third, for just only 3 papers, no stratified study was conducted for rs2981578 polymorphism. Moreover, our study is a summary of the data. We did not verify it from the level of molecular mechanism. Data from large scale multicenter epidemiological studies is still needed to confirm the relationship between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms and BC risk, and the molecular mechanism for the associations need to be elucidated further.

In conclusion, our meta-analysis based on case-control studies provides strong evidence that FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms are significantly associated with the BC risk. For rs2981582 and rs2420946, the association remained significant in Asians, Caucasians, general populations and hospital populations. However, further large scale multicenter epidemiological studies are warranted to confirm this finding and the molecular mechanism for the associations need to be elucidated further.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

We searched PubMed, Web of science and the Cochrane Library for relevant studies published before October 11, 2015. The following keywords were used: (Fibroblast Growth Factor Receptor 2 or FGFR2) and (variant\* or genotype or polymorphism or SNP) and (breast) and (cancer or carcinom\* or neoplasm\* or tumor), and the combined phrases for all genetic studies on the association between the FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk. The reference lists of all articles were also manually screened for potential studies. Abstracts and citations were screened by two researchers independently. All the eligible articles need a second screening for the full-text. The searching was done without language limitations.

Selection and exclusion criteria {#s4_2}
--------------------------------

Inclusion criteria: A study was included in this meta-analysis if it met the following criteria: *i*)independent case-control studies for humans; *ii*) the study evaluating the association between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk; *iii*) the study presenting available genotype frequencies in cancer cases and control subjects for risk estimated; *iiii*) cases should have been diagnosed by a pathological examination. We excluded comments, editorials, systematic reviews and studies lacking sufficient data or studies with male cases. If the researches were duplicated or shared in more than one study, the most recent publications were included.

Data extraction and synthesis {#s4_3}
-----------------------------

We used endnote bibliographic software to construct an electronic library of citations identified in the literature search. All the PubMed, Web of science and the Cochrane Library searches were performed using Endnote. Duplicates were found automatically by endnote and deleted manually. All data extraction were checked and calculated twice according to the inclusion criteria listed above by two independent investigators. Data extracted from the included studies were as follows: First author, year of publication, country, Ethnicity, Source of controls, Genotyping method, number of cases and controls and evidence of Hardy-Weinberg equilibrium(HWE) in controls. A third reviewer would participate if some disagreements were emerged, and a final decision was made by the majority of the votes.

Statistical analysis {#s4_4}
--------------------

All statistical analyses were performed using STATA version 11.0 software (StataCorp LP, College Station, TX) and Review Manage version 5.2.0 (The Cochrane Collaboration, 2012). Hardy-Weinberg equilibrium (HWE) was assessed by *χ^2^* test in the control group of each study \[[@R21]\]. The strength of associations between the FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk were measured by odds ratio (ORs) with 95% confidence interval (CIs). *Z* test was used to assess the significance of the ORs, *I^2^* and *Q* statistics was used to determine the statistical heterogeneity among studies. A random-effect model was used if *p* value of heterogeneity tests was no more than 0.1 (*p* ≤ 0.1), and otherwise, a fixed-effect model was selected \[[@R21], [@R22]\]. Sensitivity analyses were performed to assess the stability of the results. We used Begg\'s funnel plot and Egger\'s test to evaluate the publication bias \[[@R23], [@R24]\]. The strength of the association was estimated in the allele model, the dominant model, the recessive model, the homozygous genetic model and the heterozygous genetic model, respectively. *p*\< 0.05 was considered statistically significant. We performed subgroup according to Ethnicity and Source of controls.
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